Home › Biliary Tract Cancer
Biliary Tract Cancer clinical trials recruiting in the U.S.
40 studies for Biliary Tract Cancer are recruiting participants at sites across the United States.
Cities with the most studies
- Houston, TX18 studies
- Los Angeles, CA11 studies
- Boston, MA11 studies
- New York City, NY10 studies
- Nashville, TN9 studies
- San Antonio, TX8 studies
- Baltimore, MD8 studies
- Arlington, VA7 studies
- Pittsburgh, PA7 studies
- Washington, DC7 studies
- Baldwin Park, CA6 studies
- Madison, WI6 studies
- Columbus, OH6 studies
- Dallas, TX6 studies
- Cleveland, OH6 studies
- Philadelphia, PA6 studies
- Miami, FL5 studies
- Detroit, MI5 studies
- Louisville, KY5 studies
- Tampa, FL5 studies
- Orlando, FL4 studies
- Queens, NY4 studies
- Orange, CA4 studies
- Aurora, CO4 studies
- Seattle, WA4 studies
- San Diego, CA3 studies
- Chicago, IL3 studies
- Birmingham, AL3 studies
- Edison, NJ3 studies
- Portland, OR3 studies
- Grand Rapids, MI3 studies
- Providence, RI3 studies
- St. Louis, MO3 studies
- Tucson, AZ3 studies
- Salt Lake City, UT3 studies
- Buffalo, NY3 studies
- Denver, CO3 studies
- Santa Monica, CA3 studies
By state
- Alabama3 studies
- Arizona4 studies
- California20 studies
- Colorado7 studies
- Connecticut3 studies
- District of Columbia4 studies
- Florida14 studies
- Georgia4 studies
- Illinois5 studies
- Kentucky6 studies
- Maryland11 studies
- Massachusetts11 studies
- Michigan9 studies
- Minnesota5 studies
- Missouri4 studies
- New Jersey5 studies
- New York15 studies
- Ohio10 studies
- Oregon3 studies
- Pennsylvania10 studies
- Rhode Island3 studies
- Tennessee10 studies
- Texas23 studies
- Utah4 studies
- Virginia9 studies
- Washington5 studies
- Wisconsin6 studies
Recently updated studies
A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07265674A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07221253Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05482893A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06428409Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT05523947Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
RecruitingPhase 2
Ages 18 to 130 · All sexes · Updated Sep 23, 2026 · NCT05489211Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
RecruitingPhase 2
Ages 19 and older · All sexes · Updated Sep 22, 2026 · NCT07146646Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT06282575Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT06293898SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT07812805CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06548412AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
RecruitingPhase 1/2
Ages 18 to 75 · All sexes · Updated Sep 4, 2026 · NCT07038343A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06760819Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
RecruitingObservational study
Ages 2 to 100 · All sexes · Updated Sep 1, 2026 · NCT01950572Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection
RecruitingObservational studyHealthy volunteers welcome
Ages 18 to 99 · All sexes · Updated Aug 24, 2026 · NCT05517811Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 24, 2026 · NCT06084481A Phase 1 Study of LNCB74 in Advanced Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 21, 2026 · NCT06774963Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
RecruitingPhase 3
Ages 18 to 99 · All sexes · Updated Aug 19, 2026 · NCT06467357A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT05592626A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT06330064D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jul 30, 2026 · NCT06622057AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 29, 2026 · NCT06219941A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
RecruitingPhase 2
Ages 8 and older · All sexes · Updated Jul 27, 2026 · NCT05503797Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)
Recruiting
Ages 18 and older · All sexes · Updated Jul 2, 2026 · NCT06101277A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 29, 2026 · NCT07458347From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.